Literature DB >> 8214225

Clinical research, prophylaxis, therapy, and care for HIV disease in Africa.

K M De Cock1, S B Lucas, S Lucas, J Agness, A Kadio, H D Gayle.   

Abstract

By the end of the century, citizens of resource-poor countries will constitute 90% of the world's human immunodeficiency virus (HIV)-infected people. Clinical management of such persons in developing countries has been neglected; most AIDS research has concentrated on epidemiology, and donor agencies have generally invested in the prevention of HIV infection. The heavy burden of HIV disease in Africa requires that care for AIDS be addressed, and prevention and care should be seen as interrelated. Prevention and treatment of tuberculosis, the commonest severe infection in persons with AIDS in Africa, illustrate this interrelationship. We outline priorities for applied research on the management of HIV disease in a resource-poor environment, and discuss prophylaxis, therapy for opportunistic diseases, terminal care, and use of antiretroviral therapy. Research should define the standard of care that can realistically be demanded for HIV disease in a resource-poor environment. Research and public health programs for AIDS in developing countries must address AIDS care and attempt to reduce the widening gap between interventions available for HIV-infected persons in different parts of the world.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214225      PMCID: PMC1694848          DOI: 10.2105/ajph.83.10.1385

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  17 in total

Review 1.  Management issues for patients with HIV infection in Africa.

Authors:  E T Katabira; K R Wabitsch
Journal:  AIDS       Date:  1991       Impact factor: 4.177

2.  AIDS in Africa: problems for research and researchers.

Authors:  D Serwadda; E Katongole-Mbidde
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

Review 3.  AIDS in Uganda--clinical and social features.

Authors:  R W Goodgame
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

4.  Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.

Authors:  D W Cameron; J N Simonsen; L J D'Costa; A R Ronald; G M Maitha; M N Gakinya; M Cheang; J O Ndinya-Achola; P Piot; R C Brunham
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

5.  Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987.

Authors:  J E Harris
Journal:  JAMA       Date:  1990-01-19       Impact factor: 56.272

6.  Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons.

Authors:  S P Blatt; C R Lucey; C A Butzin; C W Hendrix; D R Lucey
Journal:  JAMA       Date:  1993-02-03       Impact factor: 56.272

7.  Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.

Authors:  R S Wallis; M Vjecha; M Amir-Tahmasseb; A Okwera; F Byekwaso; S Nyole; S Kabengera; R D Mugerwa; J J Ellner
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

8.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

9.  Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya.

Authors:  C F Gilks; R J Brindle; L S Otieno; P M Simani; R S Newnham; S M Bhatt; G N Lule; G B Okelo; W M Watkins; P G Waiyaki
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more
  6 in total

1.  Where is the M in MTCT? The broader issues in mother-to-child transmission of HIV.

Authors:  A Rosenfield; E Figdor
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

2.  When ideals meet reality--the global challenge of HIV/AIDS.

Authors:  R J Biggar
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

3.  HIV and AIDS in Africa. Research priorities should not be limited to prophylaxis.

Authors:  R Colebunders; H Van Renterghem; A Buvé
Journal:  Am J Public Health       Date:  1994-07       Impact factor: 9.308

4.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

5.  HIV and AIDS in Africa. 1. Assisting those in the early stages of HIV infection.

Authors:  S Foster
Journal:  Am J Public Health       Date:  1994-07       Impact factor: 9.308

6.  Contribution of tuberculosis to slim disease in Africa.

Authors:  S B Lucas; K M De Cock; A Hounnou; C Peacock; M Diomande; M Hondé; A Beaumel; L Kestens; A Kadio
Journal:  BMJ       Date:  1994-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.